- Report of University Hospital Hradec Králové to the clinical trial protocol No: 97280Publication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. VOS-AML-301Publication without faculty affiliation
- Single-agent cytarabine is insufficient for the treatment of human mantle cell lymphoma in mouse xenograft model2016 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma2018 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- TRAIL-induced apoptosis of HL60 leukemia cells: two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNF alpha but not to idarubicin and cytarabine2009 | First Faculty of Medicine
- Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma2021 | First Faculty of Medicine
- Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents2014 | First Faculty of Medicine
- Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia2012 | First Faculty of Medicine
- Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study2018 | Second Faculty of Medicine
- Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16)2011 | Second Faculty of Medicine
- Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Aplasia After Cladribine/Cytarabine Chemotherapy for Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome2019 | First Faculty of Medicine
- Intermediate Dose Cytarabine/Idarubicin Induction and Non-Ara-C Containing Intensification in Newly Diagnosed De novo Adult Acute Myeloid Leukemia Under 60 YearsPublication without faculty affiliation
- TRAIL-induced apoptosis of HL60 leukemia cells: two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNF alpha but not to idarubicin and cytarabine2009 | Publication without faculty affiliation
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia2012 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy2021 | Third Faculty of Medicine
- Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Munster study group2019 | Second Faculty of Medicine
- Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Munster Study Group2015 | Central Library of Charles University
- Additional treatment with 2-Chloro-2-Deoxyadenosine during consolidation in children with high-risk acute myeloid leukemia does not improve survival2015 | Second Faculty of Medicine
- Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group2013 | Publication without faculty affiliation
- Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study2020 | Faculty of Medicine in Hradec Králové
- Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial2020 | Third Faculty of Medicine
- Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 20042013 | Second Faculty of Medicine
- Monitoring of Cardiotoxicity during Induction Chemotherapy in Acute Leukemia with Biochemical Markers2005 | First Faculty of Medicine
- The Use Biochemical Markers in Cardiotoxicity Monitoring in Patients Treated for Leukemia2005 | First Faculty of Medicine
- Experimental therapy of B-cell Non-Hodgkin's lymphonasPublication without faculty affiliation
- Chemoresistant myeloid sarcoma responding to salvage therapy with combined azacitidine and venetoclax2022 | First Faculty of Medicine
- Treatment of Relapsed and Refractory Hodgkin Lymphoma - Recommendations of the Czech Hodgkin Lymphoma Study Group2016 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel2012 | Second Faculty of Medicine
- Acute myeloid leukemia with variant t(8;10;21)2022 | Third Faculty of Medicine
- Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial2023 | Third Faculty of Medicine